BC-Predict: Providing breast cancer risk as part of the NHS BSP
Research type
Research Study
Full title
Breast Cancer (BC) Predict - Providing breast cancer risk as part of the national breast cancer screening programme: building an evidence base on benefits and harms to inform a decision to implement
IRAS ID
239199
Contact name
Gareth Evans
Contact email
Sponsor organisation
Manchester University NHS Foundation Trust
Duration of Study in the UK
2 years, 1 months, 30 days
Research summary
Research Summary:
The National Institute for Health and Care Excellence (NICE) states that women at high-risk of breast cancer should have more frequent breast mammography (x-ray) screening and be offered risk-reducing treatment with the medicines tamoxifen, raloxifene or anastrozole. However women at increased risk of breast cancer in the NHS Breast Screening Programme (NHSBSP) cannot be offered prevention drugs or extra screening as the screening programme does not currently estimate or inform women of their risk.
This research aims to: automate the breast cancer risk estimation process so that it is feasible for roll-out in the wider NHSBSP and evaluate the benefits and harms of this approach for women so that consensus may be reached between key stakeholders about whether the benefits of this outweigh the harms and if so, how to implement this in the NHSBSP.
A proportion of women attending breast screening will be invited to participate in the BC-Predict study. Those opting to participate will join via online consent, following which they will complete the online breast cancer risk estimation tool. Women may also opt to have a mammogram, though this is not compulsory. Those who have a mammogram will have breast density assessed from the mammogram and this will be combined with the information they provide in the online questionnaire to estimate their breast cancer risk. Risk information will be sent to participants via letter after confirmation of a normal mammogram result (approximately 6-weeks after consent).
Uptake to additional screening and chemoprevention will be measured in those who have participated in BC-Predict and this will be compared with a comparator control group. The control group of women will not be consented and recruited; population level data will instead be used.
REC name
London - Harrow Research Ethics Committee
REC reference
18/LO/0649
Date of REC Opinion
9 Jul 2018
REC opinion
Further Information Favourable Opinion